The procoagulant effects of fine particulate matter in vivo

Inhalation of fine particulate matter (<2.5 μm; fine PM) has been shown to increase the risk for cardiovascular events. In this letter, we reappraise the role of tissue factor (TF) antigen and we also summarize changes in measured coagulation proteins in humans and rodents by other studies with f...

Descripción completa

Detalles Bibliográficos
Autores principales: Kilinç, Evren, Schulz, Holger, Kuiper, Gerhardus JAJM, Spronk, Henri MH, ten Cate, Hugo, Upadhyay, Swapna, Ganguly, Koustav, Stoeger, Tobias, Semmler-Bhenke, Manuela, Takenaka, Shinji, Kreyling, Wolfgang G, Pitz, Mike, Reitmeir, Peter, Peters, Annette, Eickelberg, Oliver, Wichmann, H Erich
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068090/
https://www.ncbi.nlm.nih.gov/pubmed/21406084
http://dx.doi.org/10.1186/1743-8977-8-12
Descripción
Sumario:Inhalation of fine particulate matter (<2.5 μm; fine PM) has been shown to increase the risk for cardiovascular events. In this letter, we reappraise the role of tissue factor (TF) antigen and we also summarize changes in measured coagulation proteins in humans and rodents by other studies with fine PM. By considering all studies including ours, we conclude that monitoring the overall coagulation state by measuring capacity assays such as thrombin generation, and quantification of TF activity would be more suitable than determining single coagulation proteins (such as TF antigen) in order to better assess the systemic prothrombotic effects of fine PM.

Ejemplares similares